FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

On February 22, 2017, the U.S. Food and Drug Administration (FDA) granted approval for the use of lenalidomide as maintenance therapy after autologous hematopoietic stem cell transplantation (auto‐HSCT) for patients with multiple myeloma. The approval was based on evidence from two randomized, blind...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Pulte, Elizabeth Dianne, Dmytrijuk, Andrew, Nie, Lei, Goldberg, Kirsten B., McKee, Amy E., Farrell, Ann T., Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067941/
https://ncbi.nlm.nih.gov/pubmed/29438096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0440
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados